The Biomarker Technologies Market is projected to reach USD 69.5527489
billion by 2032 at 9.20% CAGR during the forecast period 2023-2032.
The term biomarker is usually used to define a measurable indicator of
some biological state or condition. It is also referred to a substance whose
detection indicates the presence of a living organism. Biomarkers are used for
diagnosis and clinical decision making in cancer, diabetes, and cardiovascular
and neurological diseases. The market for biomarker technologies is growing
worldwide due to drivers such as increased occurrence of above diseases,
advances in the area of medical technologies, governmental initiatives
supporting research in the area of biomarker technologies, and increasing uses
of biomarkers to increase the accuracy of disease diagnosis. However, high
capital investments required for the discovery, development of biomarkers, and
the high cost of biomarkers are restraining the growth of the biomarker
technologies market.
Major Key
Players:
Market Research Future (MRFR) recognizes the
following companies as Biomarker Technologies Market Players are Abbott Laboratories, Agilent
Technologies (U.S.), Thermo Fisher Scientific (U.S.), Roche (Switzerland),
Waters Corporation (U.S.), Danaher Corporation (U.S.), Shimadzu Corporation
(Japan), Siemens Healthcare, and Bio-Rad Laboratories
(U.S.).
Segment Analysis
The global biomarker technology market is segmented
on the basis of product type, profiling technology, disease application, and
research areas. Considering product type, the market is segmented into
consumables, instruments, services, and software/informatics.
By profiling technology, the market is segmented into
immunoassay, PCR, imaging technology, mass spectrometry, NGS, chromatography,
cytogenetics, and other technologies. Based on immunoassay, the market is again
segmented into ELISA, western blot, and protein microarray.
With reference to disease application, the market is
segmented into cancer, infectious disease, autoimmune diseases, neurological,
cardiovascular disorders, and other disorders.
On account of research areas, the market is segmented
into genomic biomarkers, Proteomics, Metabolomics, and other research areas. Metabolomics is further
segmented into lipidomic and others.
Based on region the market is segmented into
Americas, Europe, Asia Pacific, and the Middle East and Africa. The American
region is segmented into North America and South America. Similarly, Europe is
segmented into Western Europe and Eastern Europe.
Regional Analysis
Americas has the largest market
share in the biomarker technologies market. The increasing prevalence of
cancer, cardiovascular diseases, neurological as well as autoimmune diseases,
and rising geriatric population are likely to enhance the growth of the biomarker
technologies market. For instance, the National Cancer Institute (NCI)
had stated that 1,666,540 new cases of cancer were reported during 2014 in the
United States. Thus, this increasing patient pool will enhance the market
growth during the forecast period. Additionally, factors such as increasing
government initiatives and funding for research and development in advanced
medical treatment options, and availability of favorable reimbursement policies
are likely to propel the growth of the biomarker technologies market in the
American region. Furthermore, according to CMS (Centers for Medicare and
Medicaid Services) the U.S. health care spending increased by 4.3 percent to
reach USD 3.3 trillion per person in 2016. Thus, increasing per capita income
of individuals as well as rising healthcare spending will aid up the market
growth in Americas.
Europe is the second largest
market leader and holds a healthy share in the global biomarker technologies
market. The European market is expected to exhibit a sturdy growth rate during
the forecast period owing to the availability of advanced treatment facilities
and established healthcare infrastructure, along with the growing need for
efficient and accurate diagnosis. Furthermore, according to the Cancer Research
U.K., there were around 9, 921 cases of cancer diagnosed in 2015. The
increasing occurrence of cancer is expected to have a positive impact on the
biomarker technologies market due to its wide usage in cancer. This impact will
enhance the biomarker technologies market in Europe.
Asia Pacific is expected to be
the fastest emerging market. Factors such as the increasing prevalence of
chronic diseases are the major driver for the market growth. For instance, in
accordance with the International Diabetes Federation, nearly 382 million
people had diabetes in 2013 worldwide. This is expected to reach around 500
million by the end of 2035. China and India are the first and second most
affected countries with diabetes. This rising number of diabetic patients can
lead to the increasing patient number with cardiovascular diseases. So, these
countries are expected to be the fastest growing regions due to the increasing
patient pool, raising awareness about health, and availability of new treatment
methods.
About Market Research
Future
At Market Research Future (MRFR), we enable our
customers to unravel the complexity of various industries through our Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and Market Research &
Consulting Services.
MRFR team have supreme objective to provide the
optimum quality market research and intelligence services to our clients. Our
market research studies by products, services, technologies, applications, end
users, and market players for global, regional, and country level market
segments, enable our clients to see more, know more, and do more, which help to
answer all their most important questions.
In order to stay updated with technology and work process
of the industry, MRFR often plans & conducts meet with the industry experts
and industrial visits for its research analyst members.
Contact us:
Market Research Future
(part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 646 845 9312
